Freund's adjuvant: Difference between revisions
Content deleted Content added
m →Mechanism: WP:CHECKWIKI error fix for #61. Punctuation goes before References. Do general fixes if a problem exists. - using AWB (10480) |
Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.9.5 |
||
| (38 intermediate revisions by 25 users not shown) | |||
| Line 1: | Line 1: | ||
{{Technical|date=May 2021}} |
|||
'''Freund's adjuvant''' is a solution of [[antigen]] [[emulsified]] in [[mineral oil]] and used as an [[immunopotentiator]] (booster). The '''complete form''', Freund's Complete Adjuvant |
'''Freund's adjuvant''' is a solution of [[antigen]] [[emulsified]] in [[mineral oil]] and used as an [[immunopotentiator]] (booster). The '''complete form''', Freund's Complete Adjuvant (FCA or CFA) is composed of inactivated and dried [[Mycobacterium|mycobacteria]] (usually ''[[Mycobacterium tuberculosis|M. tuberculosis]]''), whereas the '''incomplete form''' (FIA or IFA) lacks the mycobacterial components (hence just the water in oil emulsion). It is named after [[Jules T. Freund]]. |
||
==Regulation== |
==Regulation== |
||
Freund's complete adjuvant is effective in stimulating [[cell-mediated immunity]] and leads to potentiation T helper cells that leads to the production of certain [[immunoglobulin]]s and effector T cells. Its use in humans is forbidden by regulatory authorities, due to its [[toxicity]]. |
Freund's complete adjuvant is effective in stimulating [[cell-mediated immunity]] and leads to potentiation of T helper cells that leads to the production of certain [[immunoglobulin]]s and effector T cells. Its use in humans is forbidden by regulatory authorities, due to its [[toxicity]]. In animal research there are also strict [[guideline (medical)|guidelines]] associated with its use, due to its potential for [[pain]] and tissue damage. Injections of FCA should be subcutaneous or intraperitoneal, because intradermal injections may cause [[skin ulcer]]ation and [[necrosis]]; intramuscular injections may lead to temporary or permanent [[muscle]] lesion, and intravenous injections may produce pulmonary lipid [[embolism]].{{citation needed|date=October 2017}} |
||
==Effects== |
==Effects== |
||
When administered to diabetes prone NOD mice Freund's complete adjuvant (FCA) prevented [[Diabetes mellitus type 1|juvenile-onset diabetes]].<ref>{{Citation | title=Prevention of type I diabetes in NOD mice by adjuvant immunotherapy | journal=Diabetes |volume=39 | year=1990 | pages=583–589 | url=http://diabetes.diabetesjournals.org/cgi/content/abstract/39/5/583 | pmid=2139617 | doi=10.2337/diabetes.39.5.583 | last1=Sadelain | first1=MW | last2=Qin | first2=HY | last3=Lauzon | first3=J | last4=Singh | first4=B | issue=5 }}</ref><ref>{{Citation | title=Complete |
When administered to diabetes prone non-obese diabetic (NOD) mice, Freund's complete adjuvant (FCA) prevented [[Diabetes mellitus type 1|juvenile-onset diabetes]].<ref>{{Citation | title=Prevention of type I diabetes in NOD mice by adjuvant immunotherapy | journal=Diabetes |volume=39 | year=1990 | pages=583–589 | url=http://diabetes.diabetesjournals.org/cgi/content/abstract/39/5/583 | pmid=2139617 | doi=10.2337/diabetes.39.5.583 | last1=Sadelain | first1=MW | last2=Qin | first2=HY | last3=Lauzon | first3=J | last4=Singh | first4=B | issue=5 }}</ref><ref>{{Citation | title=Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice | journal=J. Immunol. |volume=150 | year=1993 | pages=2072–2080 | url=http://www.jimmunol.org/cgi/content/abstract/150/5/2072 | pmid=8436836 | last1=Qin | first1=HY | last2=Sadelain | first2=MW | last3=Hitchon | first3=C | last4=Lauzon | first4=J | last5=Singh | first5=B | issue=5 | doi=10.4049/jimmunol.150.5.2072 | s2cid=9779509 | doi-access=free }}</ref> When combined with spleen cells, FCA was said to have reversed diabetes.<ref>{{Citation | title=Islet Regeneration During the Reversal of Autoimmune Diabetes in NOD Mice | journal=Science |volume=302 | year=2003 | pages=1223–1227 | url=http://www.sciencemag.org/cgi/content/abstract/302/5648/1223 | pmid=14615542 | doi=10.1126/science.1088949 | last1=Kodama | first1=S | last2=Kühtreiber | first2=W | last3=Fujimura | first3=S | last4=Dale | first4=EA | last5=Faustman | first5=DL | issue=5648 | bibcode=2003Sci...302.1223K | s2cid=897696 }}</ref> In 2006, these claims were confirmed that even without spleen cells FCA can restore insulin producing beta cells in pancreas of NOD mice.<ref>{{Citation | last1=Couzin | first1=J. | title=Diabetes Studies Conflict on Power of Spleen Cells | journal=Science |volume=311 | year=2006 | page=1694 | doi=10.1126/science.311.5768.1694 | issue=5768 | pmid=16556811| s2cid=10334900 | doi-access=free }}</ref> Although newspapers have described the 2006 findings as confirming the earlier experiments,<ref>{{Citation | last1=Kolata | first1=G. | title=A Controversial Therapy for Diabetes Is Verified | url=https://www.nytimes.com/2006/03/24/health/24diabetes.html | journal=The New York Times | date=March 24, 2006 | accessdate=May 3, 2010}}</ref> a report from [[National Institutes of Health|NIH]] was released on November 23, 2006, in [[Science (journal)|Science]] confirming the participation of spleen cells in reversing end-stage diabetes.<ref>[http://www.biologynews.net/archives/2006/11/23/new_data_from_nih_lab_confirms_protocol_to_reverse_type_1_diabetes_in_mice.html New data from NIH lab confirms protocol to reverse type 1 diabetes in mice], BiologyNewsNet, November 2006</ref><!-- Nov 23rd Science; need ref data for Harvard ref --><ref>Philip E. Ross, [http://www.sciam.com/article.cfm?id=putting-up-with-self Putting Up with Self], Scientific American, November 12, 2006</ref> |
||
It has also been investigated in an animal model of [[Parkinson's disease]] |
It has also been investigated in an animal model of [[Parkinson's disease]],<ref name="pmid17023164">{{Citation |vauthors=Armentero MT, Levandis G, Nappi G, Bazzini E, Blandini F |title=Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease |journal=Neurobiol. Dis. |volume=24 |issue=3 |pages=492–505 |year=2006 |pmid=17023164 |doi=10.1016/j.nbd.2006.08.016 |s2cid=7076941 |postscript=.}}</ref> or as well used in emulsion with [[Myelin oligodendrocyte glycoprotein]] (MOG), a peptide inducing [[Experimental autoimmune encephalomyelitis]] (EAE) in animal studies for efficacy testing of [[multiple sclerosis]] treatments.<ref>{{Cite journal|last1=Bittner|first1=Stefan|last2=Afzali|first2=Ali M.|last3=Wiendl|first3=Heinz|last4=Meuth|first4=Sven G.|date=2014-04-15|title=Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice|url=http://www.jove.com/video/51275/myelin-oligodendrocyte-glycoprotein-mog35-55-induced-experimental|journal=Journal of Visualized Experiments|language=en|issue=86|pages=51275|doi=10.3791/51275|issn=1940-087X|pmc=4172026|pmid=24797125}}</ref> |
||
===Mechanism=== |
===Mechanism=== |
||
FCA is known to stimulate production of [[Tumor necrosis factors|tumor necrosis factor]], which is thought to kill the [[T-cells]] responsible for the [[autoimmune]] destruction of the pancreatic [[ |
FCA is known to stimulate production of [[Tumor necrosis factors|tumor necrosis factor]], which is thought to kill the [[T-cells]] responsible for the [[autoimmune]] destruction of the pancreatic [[beta cells]]. Still in question is whether the regrowth of functional [[insulin]]-producing cells occurs due to [[differentiation (cellular)|differentiation]] and [[cell division|proliferation]] of existing [[pancreas|pancreatic]] [[adult stem cells|stem cells]], or whether the injected spleen cells re-differentiate to an insulin-producing form. [[Denise Faustman]], whose work has been central to developing the protocol, has suggested that both mechanisms may play a role. However, in experiments to verify and examine her work, Suri reported that DNA-based evidence yielded no sign that spleen cells were needed in [[pancreatic]] [[Islets of Langerhans|islet]] [[beta cells]] regeneration after the FCA treatment.<ref>{{Citation | title=Immunological Reversal of Autoimmune Diabetes Without Hematopoietic Replacement of β Cells | journal=Science |volume=311 | year=2006 | pages=1778–1780 | url=http://www.sciencemag.org/cgi/content/abstract/311/5768/1778 | pmid=16556846 | doi=10.1126/science.1123500 | last1=Suri | first1=A | last2=Calderon | first2=B | last3=Esparza | first3=TJ | last4=Frederick | first4=K | last5=Bittner | first5=P | last6=Unanue | first6=ER | issue=5768 | bibcode=2006Sci...311.1778S | s2cid=42150301 }}</ref> In pancreatic islets the β-cells regenerate following Freund's adjuvant treatment.<ref>{{cite journal |last1=Huszarik |first1=K |last2= Wright |first2=B |last3= Keller |first3=C |last4= Nikoopour |first4=E | title = Adjuvant immunotherapy increases beta cell regenerative factor Reg2 in the pancreas of diabetic mice | journal = J. Immunol. | volume = 185 | issue = 9 | pages = 5120–9 | year = 2010 | pmid=20876350 | doi = 10.4049/jimmunol.1001596 |doi-access= free }}</ref> This is related to the induction of [[Th17]] cells by adjuvant treatment and these cells produce [[Interleukin-22]] (IL-22). [[Pancreatic islets]] express high levels of IL-22 receptor and IL-22 has been shown to induce islet beta cell regeneration.<ref>{{cite journal |last1= Hill |first1=T |last2= Krougly |first2=O |last3=Nikoopour |first3=E |last4= Bellemore |first4=S | title = The involvement of interleukin-22 in the expression of pancreatic beta cell regenerative Reg genes. | journal = Cell Regeneration | year = 2013 | volume = 2 | issue = 1 | pages = 1–11 | doi = 10.1186/2045-9769-2-2 | pmid=25408874 | pmc=4230743 |doi-access=free }}</ref> |
||
==See also== |
==See also== |
||
| Line 16: | Line 17: | ||
==References== |
==References== |
||
{{ |
{{reflist|30em}} |
||
==External links== |
==External links== |
||
* [http://research.uiowa.edu/animal/?get=adjuvant Recommendations for Use and Alternatives to Freund's Complete Adjuvant]. [[University of Iowa]] |
* [http://research.uiowa.edu/animal/?get=adjuvant Recommendations for Use and Alternatives to Freund's Complete Adjuvant] {{Webarchive|url=https://web.archive.org/web/20120227081855/http://research.uiowa.edu/animal/?get=adjuvant |date=2012-02-27 }}. [[University of Iowa]] |
||
[[Category:Immunology]] |
[[Category:Immunology]] |
||
[[Category:Immune system]] |
[[Category:Immune system]] |
||
[[Category:Animal testing]] |
[[Category:Animal testing]] |
||
[[Category:Adjuvants]] |
|||
Latest revision as of 11:20, 12 May 2024
 | This article may be too technical for most readers to understand. (May 2021) |
Freund's adjuvant is a solution of antigen emulsified in mineral oil and used as an immunopotentiator (booster). The complete form, Freund's Complete Adjuvant (FCA or CFA) is composed of inactivated and dried mycobacteria (usually M. tuberculosis), whereas the incomplete form (FIA or IFA) lacks the mycobacterial components (hence just the water in oil emulsion). It is named after Jules T. Freund.
Regulation
[edit]Freund's complete adjuvant is effective in stimulating cell-mediated immunity and leads to potentiation of T helper cells that leads to the production of certain immunoglobulins and effector T cells. Its use in humans is forbidden by regulatory authorities, due to its toxicity. In animal research there are also strict guidelines associated with its use, due to its potential for pain and tissue damage. Injections of FCA should be subcutaneous or intraperitoneal, because intradermal injections may cause skin ulceration and necrosis; intramuscular injections may lead to temporary or permanent muscle lesion, and intravenous injections may produce pulmonary lipid embolism.[citation needed]
Effects
[edit]When administered to diabetes prone non-obese diabetic (NOD) mice, Freund's complete adjuvant (FCA) prevented juvenile-onset diabetes.[1][2] When combined with spleen cells, FCA was said to have reversed diabetes.[3] In 2006, these claims were confirmed that even without spleen cells FCA can restore insulin producing beta cells in pancreas of NOD mice.[4] Although newspapers have described the 2006 findings as confirming the earlier experiments,[5] a report from NIH was released on November 23, 2006, in Science confirming the participation of spleen cells in reversing end-stage diabetes.[6][7]
It has also been investigated in an animal model of Parkinson's disease,[8] or as well used in emulsion with Myelin oligodendrocyte glycoprotein (MOG), a peptide inducing Experimental autoimmune encephalomyelitis (EAE) in animal studies for efficacy testing of multiple sclerosis treatments.[9]
Mechanism
[edit]FCA is known to stimulate production of tumor necrosis factor, which is thought to kill the T-cells responsible for the autoimmune destruction of the pancreatic beta cells. Still in question is whether the regrowth of functional insulin-producing cells occurs due to differentiation and proliferation of existing pancreatic stem cells, or whether the injected spleen cells re-differentiate to an insulin-producing form. Denise Faustman, whose work has been central to developing the protocol, has suggested that both mechanisms may play a role. However, in experiments to verify and examine her work, Suri reported that DNA-based evidence yielded no sign that spleen cells were needed in pancreatic islet beta cells regeneration after the FCA treatment.[10] In pancreatic islets the β-cells regenerate following Freund's adjuvant treatment.[11] This is related to the induction of Th17 cells by adjuvant treatment and these cells produce Interleukin-22 (IL-22). Pancreatic islets express high levels of IL-22 receptor and IL-22 has been shown to induce islet beta cell regeneration.[12]
See also
[edit]References
[edit]- ^ Sadelain, MW; Qin, HY; Lauzon, J; Singh, B (1990), "Prevention of type I diabetes in NOD mice by adjuvant immunotherapy", Diabetes, 39 (5): 583–589, doi:10.2337/diabetes.39.5.583, PMID 2139617
- ^ Qin, HY; Sadelain, MW; Hitchon, C; Lauzon, J; Singh, B (1993), "Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice", J. Immunol., 150 (5): 2072–2080, doi:10.4049/jimmunol.150.5.2072, PMID 8436836, S2CID 9779509
- ^ Kodama, S; Kühtreiber, W; Fujimura, S; Dale, EA; Faustman, DL (2003), "Islet Regeneration During the Reversal of Autoimmune Diabetes in NOD Mice", Science, 302 (5648): 1223–1227, Bibcode:2003Sci...302.1223K, doi:10.1126/science.1088949, PMID 14615542, S2CID 897696
- ^ Couzin, J. (2006), "Diabetes Studies Conflict on Power of Spleen Cells", Science, 311 (5768): 1694, doi:10.1126/science.311.5768.1694, PMID 16556811, S2CID 10334900
- ^ Kolata, G. (March 24, 2006), "A Controversial Therapy for Diabetes Is Verified", The New York Times, retrieved May 3, 2010
- ^ New data from NIH lab confirms protocol to reverse type 1 diabetes in mice, BiologyNewsNet, November 2006
- ^ Philip E. Ross, Putting Up with Self, Scientific American, November 12, 2006
- ^ Armentero MT, Levandis G, Nappi G, Bazzini E, Blandini F (2006), "Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease", Neurobiol. Dis., 24 (3): 492–505, doi:10.1016/j.nbd.2006.08.016, PMID 17023164, S2CID 7076941.
- ^ Bittner, Stefan; Afzali, Ali M.; Wiendl, Heinz; Meuth, Sven G. (2014-04-15). "Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice". Journal of Visualized Experiments (86): 51275. doi:10.3791/51275. ISSN 1940-087X. PMC 4172026. PMID 24797125.
- ^ Suri, A; Calderon, B; Esparza, TJ; Frederick, K; Bittner, P; Unanue, ER (2006), "Immunological Reversal of Autoimmune Diabetes Without Hematopoietic Replacement of β Cells", Science, 311 (5768): 1778–1780, Bibcode:2006Sci...311.1778S, doi:10.1126/science.1123500, PMID 16556846, S2CID 42150301
- ^ Huszarik, K; Wright, B; Keller, C; Nikoopour, E (2010). "Adjuvant immunotherapy increases beta cell regenerative factor Reg2 in the pancreas of diabetic mice". J. Immunol. 185 (9): 5120–9. doi:10.4049/jimmunol.1001596. PMID 20876350.
- ^ Hill, T; Krougly, O; Nikoopour, E; Bellemore, S (2013). "The involvement of interleukin-22 in the expression of pancreatic beta cell regenerative Reg genes". Cell Regeneration. 2 (1): 1–11. doi:10.1186/2045-9769-2-2. PMC 4230743. PMID 25408874.